CAR T-cell Therapy
One of the most exciting and most advanced fields of development has been CAR-T, which stands for Chimeric Antigen Receptor (CAR) T-cell Therapy. In this approach, doctors collect and then use the patients' own immune cells (T-cells) to attack tumors and treat their cancer. Up until 2017, CAR-T was used for patients dealing with advanced blood cancers and was limited to small clinical trials.
The results were enough to encourage more clinical research and in 2017, the U.S. Food and Drug Administration (FDA) approved two CAR T-cell therapies, one focused on children with acute lymphoblastic leukemia (all) and the other on adults with advanced lymphomas. It's unclear what CAR T-cell therapies can do for solid tumors as the research is still early and limited to blood cancers.
Story of how CAR T was successful for a man who had refractory non-Hodgkin lymphoma.